Considering the great importance that the transcatheter aortic valve replacement (TAVR) has nowadays in the treatment of valvular heart disease, Cardiolink Group has recently reached an agreement with Meril Life Sciences Pvt. Ltd, for the distribution of the transcatheter heart valve MyVal^TM in Spain.

The transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure whereby a fully collapsible replacement valve is delivered to the valve site through a catheter. This novel technique is specially indicated in those patients with severe and symptomatic aortic stenosis that require an aortic heart valve replacement but who cannot undergo open heart surgery.

On the 3^rd of March, following a detailed analysis of the clinical and technical characteristics of the transcatheter heart valve MyVal^TM, the Cardiac Surgery Service in Complejo Hospitalario Universitario A Coruña (A Coruña, Spain), decided to conduct 3 TAVR procedures with MyVal^TM through transapical approach, achieving optimal results.

The transcatheter heart valve MyVal^TM is a biological (bovine pericardium) tri-leaflet valve specially designed for precision in outcomes. In particular, its hybrid honeycomb cell design concept and the cobalt alloy frame confer a high radial strength and radiopacity. Furthermore, it possesses unique radiopaque markers for guidance under fluoroscopy for positioning the device across the treatment site. Finally, MyVal^TM’s delivery system which is suitable for implantation by balloon expansion also plays an important role on its high precision in outcomes.